AstraZeneca earnings hit by waning cholesterol drug sales

LONDON (Reuters) - Generic competition to cholesterol fighter Crestor in the key U.S. market hit second-quarter earnings at drugmaker AstraZeneca, which is now banking on new cancer medicines to revive its fortunes.

AstraZeneca earnings hit by waning cholesterol drug sales
Read More


Bagikan Berita Ini